Streetbeat News

Revenues

JPM

JP Morgan's international retail business is performing better than expected, with plans to expand into the rest of Europe. The bank is also investing in hiring bankers for its corporate and investment banking sectors.

Portfolio Pulse from Benzinga Newsdesk

September 10, 2024 | 2:06 pm

CPB

Campbell Soup plans to make Goldfish the largest brand in its portfolio by fiscal 2027, targeting net sales of $1.3 billion.

Portfolio Pulse from Benzinga Newsdesk

September 10, 2024 | 2:03 pm

PRG

Analysts have provided mixed ratings for PROG Holdings (NYSE:PRG) over the past three months, with a recent increase in the average 12-month price target to $48.8. The company's financial performance shows challenges in revenue growth and net margin, but strong ROE and ROA.

Portfolio Pulse from Benzinga Insights

September 10, 2024 | 2:01 pm

HAE

Haemonetics (NYSE:HAE) has been analyzed by four analysts, showing a range of ratings from bullish to indifferent. The average 12-month price target is $107.5, with a high of $125 and a low of $85. Recent analyst actions include a buy rating from BTIG, a neutral rating from Citigroup, and outperform ratings from JMP Securities and Barrington Research. Haemonetics has shown a revenue growth rate of 7.98% and strong financial metrics, including a net margin of 11.41% and a ROE of 4.11%.

Portfolio Pulse from Benzinga Insights

September 10, 2024 | 2:01 pm

HRMY

In the past three months, six analysts have rated Harmony Biosciences (NASDAQ:HRMY), with all ratings being bullish. The average 12-month price target remains at $52.0, with a high of $56.00 and a low of $48.00. Analysts from UBS, Needham, and Citigroup have maintained or announced 'Buy' ratings. Harmony Biosciences shows a positive revenue trend with a 28.76% growth rate, a net margin of 6.71%, and a conservative debt-to-equity ratio of 0.35.

Portfolio Pulse from Benzinga Insights

September 10, 2024 | 2:01 pm

DAVE

Analysts have evaluated Dave (NASDAQ:DAVE) over the past three months, with a mix of bullish and somewhat bullish ratings. The average 12-month price target is $60.57, a decrease from the previous $63.60. Dave has shown strong financial performance with notable revenue growth and efficient cost management, but its debt-to-equity ratio is higher than the industry average.

Portfolio Pulse from Benzinga Insights

September 10, 2024 | 2:01 pm

GWRE

Guidewire Software (NYSE:GWRE) has outperformed the market over the past 10 years with an average annual return of 14.4%, resulting in a $1000 investment growing to $3,780.88. The company's current market cap is $13.94 billion.

Portfolio Pulse from Benzinga Insights

September 10, 2024 | 2:00 pm

VRSK

Verisk Analytics (NASDAQ:VRSK) has significantly outperformed the market over the past 15 years, with an average annual return of 16.66%. A $100 investment in VRSK 15 years ago would be worth $1,009.09 today, highlighting the power of compounded returns.

Portfolio Pulse from Benzinga Insights

September 10, 2024 | 2:00 pm

PAYO

Analysts have recently updated their ratings for Payoneer Global (NASDAQ:PAYO), with a majority being bullish. The average 12-month price target has increased to $8.75, reflecting a 12.9% rise. Payoneer has shown strong revenue growth but faces challenges in profitability and returns.

Portfolio Pulse from Benzinga Insights

September 10, 2024 | 2:00 pm

JPM

JP Morgan President Daniel Pinto expressed optimism about the U.S. economy, noting that consumers are in good shape with revolving credit lower than pre-pandemic levels. He highlighted growth opportunities in the premium segment, autos, and emphasized wealth management as a key focus area.

Portfolio Pulse from Benzinga Newsdesk

September 10, 2024 | 2:00 pm